Therapeutic HIV Vaccines with Toll-Like Receptor Agonists: Immune Responses and Viral Reservoir Reduction

Alberta Jeanne N.

School of Applied Health Sciences Kampala International University Uganda

                                                                       ABSTRACT
The advent of antiretroviral therapy has transformed Human Immunodeficiency Virus infection from a fatal diagnosis into a manageable chronic condition, yet the virus persisted in latent reservoirs that remained untouched by current treatment strategies. Despite decades of viral suppression, patients cannot safely discontinue therapy without experiencing rapid viral rebound, underscoring the urgent need for curative interventions. This review examined the emerging role of toll-like receptor agonists as adjuvants in therapeutic HIV vaccines designed to reduce or eliminate viral reservoirs. This article synthesized current literature on TLR agonist based therapeutic vaccines, examining preclinical studies, clinical trial data, and immunological mechanisms underlying their potential efficacy. The findings revealed that TLR agonists, particularly those targeting TLR7, TLR8, and TLR9, demonstrated significant capacity to reverse viral latency, enhance HIV specific cytotoxic T lymphocyte responses, and promoted innate immune activation that collectively contributed to measurable reductions in reservoir size. Clinical trials had shown promising but variable results, with some patients achieving prolonged periods of viral control following analytical treatment interruption. The integration of TLR agonists into therapeutic vaccine platforms represented a scientifically rational approach to achieving functional HIV cure, though significant challenges regarding safety, efficacy, and patient selection remained. Future research should prioritize combination immunotherapeutic strategies that synergistically target multiple aspects of viral persistence.

Keywords: Therapeutic HIV vaccines, Toll like receptor agonists, Viral reservoir, Latency reversal, Functional cure.

CITE AS: Alberta Jeanne N. (2026). Therapeutic HIV Vaccines with Toll-Like Receptor Agonists: Immune Responses and Viral Reservoir Reduction. Research Output Journal of Public Health and Medicine 6(1):114-124. https://doi.org/10.59298/ROJPHM/2026/61114124